Ypsomed Holding AG (YPSN) AI Stock Analysis

• Market Cap: CHF5.94B
• Dividend Yield: 0.5%
• Average Volume (3M): 14.25K
• Price to Earnings (P/E): 66.3
• Beta (1Y): 0.60
• Revenue Growth: 36.54%
• EPS Growth: 11.60%
• Country: CH
• Employees: 2,600
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 4.02
• Shares Outstanding: 13,649,739
• 10 Day Avg. Volume: 12,251
• 30 Day Avg. Volume: 14,252
• PEG Ratio: 3.69
• Price to Book (P/B): 8.38
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -98.97
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF434.07
• Price Target Upside: 4.34% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 73 Outperform
• Price Target: CHF467.00 ▲(12.26%Upside)

Ypsomed Holding AG's strong financial performance and positive technical indicators are notable strengths, leading to a favorable stock score. However, the high P/E ratio and low dividend yield pose valuation concerns, which slightly temper the overall score.

Ypsomed Holding AG Business Overview & Revenue Model

Company Description

Ypsomed Holding AG (YPSN) is a Swiss company that specializes in the development and manufacturing of injection and infusion systems for self-medication, offering products and services primarily in the healthcare and medical technology sectors. The company's core products include pen injectors, autoinjectors, and insulin pumps, which are used for the administration of various types of medications, including insulin for diabetes management. Ypsomed also provides contract manufacturing services and solutions for pharmaceutical and biotechnology companies.

How the Company Makes Money

Ypsomed makes money through the sale of its proprietary injection and infusion systems directly to healthcare providers and patients, as well as through partnerships with pharmaceutical and biotechnology companies who use Ypsomed's devices for drug delivery. Key revenue streams include the sales of insulin pumps and related supplies, pen injectors, and autoinjectors. The company also benefits from long-term contracts and collaborations with major pharmaceutical companies, which provide a steady source of income through the licensing of its technologies and the provision of manufacturing services.

Ypsomed Holding AG Financial Statement Overview

Summary

Ypsomed Holding AG demonstrates strong revenue growth and profitability, with solid EBIT and EBITDA margins indicating effective cost management. The balance sheet is healthy with a reasonable debt-to-equity ratio and strong ROE. However, the negative free cash flow due to high capital expenditures highlights potential cash flow management challenges.

Income Statement

Ypsomed Holding AG has demonstrated notable revenue growth, with Total Revenue increasing from CHF 548.5 million in 2024 to CHF 748.9 million in 2025, representing a growth rate of 36.54%. The company's Gross Profit Margin is robust at 39.00%, and the Net Profit Margin is healthy at 11.69%, reflecting strong profitability. EBIT and EBITDA Margins are also solid at 15.08% and 25.49%, respectively, indicating effective cost management and operational efficiency.

Balance Sheet

The company's Debt-to-Equity Ratio is 0.39, which indicates a reasonable level of leverage. The Return on Equity (ROE) is strong at 12.88%, showcasing effective utilization of shareholder funds. The Equity Ratio stands at 51.08%, highlighting a balanced capital structure with a significant portion funded by equity, contributing to financial stability.

Cash Flow

Ypsomed Holding AG's Free Cash Flow is negative at CHF -128.9 million, primarily due to high capital expenditures. However, the Operating Cash Flow to Net Income Ratio is favorable at 1.69, suggesting that the company's operations are generating sufficient cash relative to its net income. The Free Cash Flow to Net Income Ratio is negative, indicating challenges in converting net income into free cash flow, which might be a concern if sustained.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	748.87M	548.46M	497.46M	464.84M	403.66M
Gross Profit	292.07M	189.05M	140.59M	113.82M	94.83M
EBITDA	190.90M	161.78M	137.51M	92.48M	63.86M
Net Income	87.50M	78.37M	51.27M	23.11M	5.81M
Balance Sheet
Total Assets	1.33B	1.10B	861.88M	756.91M	717.68M
Cash, Cash Equivalents and Short-Term Investments	36.49M	74.02M	25.22M	17.04M	22.41M
Total Debt	267.00M	256.00M	157.00M	267.00M	215.00M
Total Liabilities	650.66M	483.66M	291.57M	356.63M	313.54M
Stockholders Equity	679.68M	617.74M	562.33M	392.54M	395.38M
Cash Flow
Free Cash Flow	-128.95M	-32.09M	-39.64M	-41.72M	-40.75M
Operating Cash Flow	148.20M	163.22M	129.53M	85.71M	85.83M
Investing Cash Flow	-267.27M	-195.07M	-122.02M	-125.70M	-106.91M
Financing Cash Flow	82.25M	81.07M	1.26M	38.12M	26.67M

Ypsomed Holding AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 416.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:YPSN, the sentiment is Positive. The current price of 416 is above the 20-day moving average (MA) of 414.75, above the 50-day MA of 395.25, and above the 200-day MA of 367.88, indicating a bullish trend. The MACD of 7.59 indicates Positive momentum. The RSI at 73.05 is Negative, neither overbought nor oversold. The STOCH value of 60.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:YPSN.

Ypsomed Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GALE	77 Outperform	CHF4.37B	24.33		2.61%	4.67%	-35.91%
SFZN	75 Outperform	CHF4.03B	24.07	18.36%	4.65%	1.82%	39.11%
YPSN	73 Outperform	CHF5.94B	66.29	13.49%	0.50%	36.54%	11.60%
MOVE	66 Neutral	$2.76B	40.16	20.81%	0.50%	13.35%	50.65%
Sector *	65 Neutral	¥347.63B	11.07	-2.99%	2.55%	11.77%	-10.16%
TECN	61 Neutral	CHF2.12B	30.51	4.84%	1.81%	-13.04%	-48.74%
MEDX	61 Neutral	CHF505.88M	―		4.08%	-0.55%	-2691.43%